ArticleTranslational lung cancer research2019

KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit.

Amy Lauren Cummings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.